Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors